|
Post by mnkdnewb on Mar 2, 2017 9:04:12 GMT -5
Great investment advice. I'm sure Buffet relies on "hope" when a stock is in the middle of tanking. He would never sell because things always turn around If you are going to use the man's name the least you can do is learn the proper spelling. Buffett's great purchase of GEICO is an excellent example of buying on the cheap while "tanking". Any other nonsense you care to vomit? Sure, just hold tight and ignore the noise, you may be a winner!
|
|
|
Post by silentknight on Mar 2, 2017 9:04:19 GMT -5
So we go to ~ $2.50 tomorrow. With downward pressure, that's certainly not much room to maneuver before they flirt with another delisting notice. As someone else pointed out, fairly adeptly, I find imminent dilution to be unlikely given the 1-5 ration, as opposed to 1-10. We'll see how the price holds up but I expect it to go down. No extension either. Imagine that. Yep, they just needed it in their back pocket to file for an extension. Nothing to see here. Extension coming. No R/S. Period. Just a bunch of Fudsters. You would expect that this action, coming immediately after the vote, would cause a few folks to take a look at their postings and stop posting wishes as fact, but human nature being as it is, I doubt it. Bulls will be bulls, bears will be bears, and bulls who were fooled one time too many will be voracious bears. I'm shocked at the 5-1. A 10-1 gives no more bad mojo than a 5-1 and would allow immediate execution of the At the Money facility for its full potential. $50M would fun another 6 months. Yes, some people just can't be reasoned with. I share your amazement at 5-1 vs. 10-1. I hope the BoD made the call based on insider knowledge. If not, MNKD will probably be facing the same issues again that warranted the R/S to begin with. I think the 5-1 was a bad call but this is the same BoD that's seen the company's worth whittle away under their watch, after all. I'm not surprised.
|
|
|
Post by surplusvalue on Mar 2, 2017 11:07:49 GMT -5
So we go to ~ $2.50 tomorrow. With downward pressure, that's certainly not much room to maneuver before they flirt with another delisting notice. As someone else pointed out, fairly adeptly, I find imminent dilution to be unlikely given the 1-5 ration, as opposed to 1-10.
We'll see how the price holds up but I expect it to go down. No extension either. Imagine that. That was me. From the very beginning in this thread and others, I asked why the range , why the 1 for 3 etc . Everyone was so sure it was going to be 1 for 10 and then dilution. I pointed out the possibility that they may not be using the RS for setting up dilution conditions. In this thread I stated that I wasnt so sure they it was going to be 1 for 10 and that if it wasnt then the likelihood of immediate dilution was remote. They used the RS for the listing issue. This is why I'm not surprised by the 1 for 5 at all. Let's see if they also have something to help support the RS to help limit any downward pressure on the SP.
|
|
|
Post by peppy on Mar 2, 2017 12:16:22 GMT -5
So we go to ~ $2.50 tomorrow. With downward pressure, that's certainly not much room to maneuver before they flirt with another delisting notice. As someone else pointed out, fairly adeptly, I find imminent dilution to be unlikely given the 1-5 ration, as opposed to 1-10. We'll see how the price holds up but I expect it to go down. No extension either. Imagine that. Yep, they just needed it in their back pocket to file for an extension. Nothing to see here. Extension coming. No R/S. Period. Just a bunch of Fudsters. You would expect that this action, coming immediately after the vote, would cause a few folks to take a look at their postings and stop posting wishes as fact, but human nature being as it is, I doubt it. Bulls will be bulls, bears will be bears, and bulls who were fooled one time too many will be voracious bears. I'm shocked at the 5-1. A 10-1 gives no more bad mojo than a 5-1 and would allow immediate execution of the At the Money facility for its full potential. $50M would fun another 6 months.quote: $50M would fun another 6 months. reply: Typo, or are you just smarter than the average bear and having fun with us?
|
|
|
Post by thekid2499 on Mar 2, 2017 12:22:20 GMT -5
I hope MNKD knows something about script numbers tomorrow that we don't. Because if they are flat again, there is going to be significant downward pressure tomorrow immediately on the stock price.
|
|
|
Post by derek2 on Mar 2, 2017 12:27:28 GMT -5
Yep, they just needed it in their back pocket to file for an extension. Nothing to see here. Extension coming. No R/S. Period. Just a bunch of Fudsters. You would expect that this action, coming immediately after the vote, would cause a few folks to take a look at their postings and stop posting wishes as fact, but human nature being as it is, I doubt it. Bulls will be bulls, bears will be bears, and bulls who were fooled one time too many will be voracious bears. I'm shocked at the 5-1. A 10-1 gives no more bad mojo than a 5-1 and would allow immediate execution of the At the Money facility for its full potential. $50M would fun another 6 months.quote: $50M would fun another 6 months. reply: Typo, or are you just smarter than the average bear and having fun with us?
HAHAHA!!! 6 months funds for MNKD, 6 months fun (paycheck) for executives & board members. Although if I'm going to joke around - MNKD has gone from selling standard proof shares (they've sold $20M worth of Afrezza, but $2 Billion worth of shares) to now selling over-proof cask strength shares - special distiller's edition! That 90% that disappeared over the last 2 years? It's the angel's share!
|
|
|
Post by peppy on Mar 2, 2017 12:34:00 GMT -5
quote: $50M would fun another 6 months. reply: Typo, or are you just smarter than the average bear and having fun with us?
HAHAHA!!! 6 months funds for MNKD, 6 months fun (paycheck) for executives & board members. Although if I'm going to joke around - MNKD has gone from selling standard proof shares (they've sold $20M worth of Afrezza, but $2 Billion worth of shares) to now selling over-proof cask strength shares - special distiller's edition! That 90% that disappeared over the last 2 years? It's the angel's share!we know. What is your take? Why is such a fine insulin in terms of glycemic control not selling? Inhaling is just the frosting on the cake. How did you know it would not sell? My thinking was bingo. then average down. then look at those glucose monitors.
|
|
|
Post by brentie on Mar 2, 2017 12:45:52 GMT -5
I hope MNKD knows something about script numbers tomorrow that we don't. Because if they are flat again, there is going to be significant downward pressure tomorrow immediately on the stock price. Not to worry, we can always blame it on the four day week.
|
|
|
Post by derek2 on Mar 2, 2017 14:07:15 GMT -5
HAHAHA!!! 6 months funds for MNKD, 6 months fun (paycheck) for executives & board members. Although if I'm going to joke around - MNKD has gone from selling standard proof shares (they've sold $20M worth of Afrezza, but $2 Billion worth of shares) to now selling over-proof cask strength shares - special distiller's edition! That 90% that disappeared over the last 2 years? It's the angel's share!we know. What is your take? Why is such a fine insulin in terms of glycemic control not selling? Inhaling is just the frosting on the cake. How did you know it would not sell? My thinking was bingo. then average down. then look at those glucose monitors.
Well, explaining it and having you agree with the explanation will be two entirely different things. I fully believe that you'll understand my explanation, but it will not agree with your view on Afrezza. That's okay - we're all free to think as we will. But hey, at the risk of being branded a "fudster" or whatever, and being run out of town on a rail, I shall answer your question with an old, old post of mine. (Also, the "angel's share" was the loss of 90% of market cap, similar to whiskey being lost to evaporation while being aged in barrels) I wrote this after the Affinity trials were released (and before approval) Now, I received feedback at the time that the trials were poorly designed, and that far more than 37% of users would have great success with Afrezza after approval and market release. Well, what's happened? You have a small number of enthusiastic users (Sam, Eric, Spiro, etc) for whom Afrezza works well. Then you have, week after week, flat line Rx. What does that mean? Well, it means no retention. If new users stuck around, Afrezza sales would grow and grow. For every new user, one drops out. I suspect that there's a core group of users (maybe 2500) that drive 200 or so of weekly Rx. The other 50 Rx are driven by users that start and then discontinue. Pretty easy math, really. The Rx numbers - very stable numbers - point to a confirmation of the efficacy from the trials. Don't believe me? Believe Matt Pfeffer. He recently quoted efficacy as one of the top two barriers to sales. Now - I don't disagree with you. Afrezza is inded a fine insulin. It is not, however: 1. A superior insulin 2. Weight advantageous (maybe a bit for T1) 3. Without hypo risk 4. Without need for refrigeration 5. Exactly like a human pancreas (only mimics 1st phase panic response to huge sugar pulse, not to natural meal) 6. Free from need of titration You have been told all of these things by MNKD management at one time or another and they have never publicly corrected themselves, other than by signing off on the label that the FDA _and_ MNKD developed. The "You have to try hard to have a hypo with Afrezza" is brazen spin, based on a single trial in which T2s were given 4 units. That's dangerous for a T1 to hear and then act on. peppy, I know that you will agree that 4 units is a negligible amount to give a T2, given their insulin resistance (I, for example, take 45 units prandial at meals and 70 units basal once a day. Hey - down from 50 and 75 two months ago since I've started on Forxiga). It was a half truth with possible nasty consequences. How did I know it wouldn't sell? I didn't, that's why I took a bath on the shares and calls that I owned, right along with everybody else. I was smart enough to see the flaws yet not wise enough to get out of the way. I thought despite the lower efficacy, MNKD could capture 5% of the prandial market, which would have supported a $15 share price. The story is not over, and I have for years said that 2017 will tell the tale. I'm still watching.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Mar 2, 2017 14:15:46 GMT -5
we know. What is your take? Why is such a fine insulin in terms of glycemic control not selling? Inhaling is just the frosting on the cake. How did you know it would not sell? My thinking was bingo. then average down. then look at those glucose monitors.
Well, explaining it and having you agree with the explanation will be two entirely different things. I fully believe that you'll understand my explanation, but it will not agree with your view on Afrezza. That's okay - we're all free to think as we will. But hey, at the risk of being branded a "fudster" or whatever, and being run out of town on a rail, I shall answer your question with an old, old post of mine. (Also, the "angel's share" was the loss of 90% of market cap, similar to whiskey being lost to evaporation while being aged in barrels) I wrote this after the Affinity trials were released (and before approval) Now, I received feedback at the time that the trials were poorly designed, and that far more than 37% of users would have great success with Afrezza after approval and market release. Well, what's happened? You have a small number of enthusiastic users (Sam, Eric, Spiro, etc) for whom Afrezza works well. Then you have, week after week, flat line Rx. What does that mean? Well, it means no retention. If new users stuck around, Afrezza sales would grow and grow. For every new user, one drops out. I suspect that there's a core group of users (maybe 2500) that drive 200 or so of weekly Rx. The other 50 Rx are driven by users that start and then discontinue. Pretty easy math, really. The Rx numbers - very stable numbers - point to a confirmation of the efficacy from the trials. Don't believe me? Believe Matt Pfeffer. He recently quoted efficacy as one of the top two barriers to sales. Now - I don't disagree with you. Afrezza is inded a fine insulin. It is not, however: 1. A superior insulin 2. Weight advantageous (maybe a bit for T1) 3. Without hypo risk 4. Without need for refrigeration 5. Exactly like a human pancreas (only mimics 1st phase panic response to huge sugar pulse, not to natural meal) 6. Free from need of titration You have been told all of these things by MNKD management at one time or another and they have never publicly corrected themselves, other than by signing off on the label that the FDA _and_ MNKD developed. The "You have to try hard to have a hypo with Afrezza" is brazen spin, based on a single trial in which T2s were given 4 units. That's dangerous for a T1 to hear and then act on. peppy , I know that you will agree that 4 units is a negligible amount to give a T2, given their insulin resistance (I, for example, take 45 units prandial at meals and 70 units basal once a day. Hey - down from 50 and 75 two months ago since I've started on Forxiga). It was a half truth with possible nasty consequences. How did I know it wouldn't sell? I didn't, that's why I took a bath on the shares and calls that I owned, right along with everybody else. I was smart enough to see the flaws yet not wise enough to get out of the way. I thought despite the lower efficacy, MNKD could capture 5% of the prandial market, which would have supported a $15 share price. The story is not over, and I have for years said that 2017 will tell the tale. I'm still watching. AfrezzaUser's take on hypos with Afrezza: afrezzauser.com/testing-the-limits-of-afrezza-unbelievable/
|
|
|
Post by dreamboatcruise on Mar 2, 2017 14:37:33 GMT -5
promann at this point you have the correct attitude: by not selling there is no guarantee that you will recoup your $, however, if you were to sell you would be guaranteed a permanent loss. Hold tight and ignore the noise, you may be a winner! Though in general that position is almost universally cited by successful investors as a bad strategy grounded in emotion and often leading to significant losses that are hard to make up for with winners. That is an "in general" comment... doesn't mean selling MNKD here is wise. I am holding. Though I certainly wouldn't be giving advise to others that this is wise. I'll only weigh in on that in hindsight a year from now. Only thing I would tell potential investors is that MNKD is a high risk, high potential reward stock, and don't bet money you aren't willing to lose.
|
|
|
Post by peppy on Mar 2, 2017 14:46:22 GMT -5
Derek, darn good reply. Thank you for the reply.
Holy Mackerel that seems like a fair share of insulin you are taking. It doesn't seem to be hurting your brain cells. peace.
added: any chance Afrezza will help? (I know I am terrible)
|
|
|
Post by n8 on Mar 2, 2017 14:46:58 GMT -5
dreamboatcruise well said. I have also been told that investing is 10% skill and 90% luck. I dont have much skill nor is my luck so now what the hell do I do? My gut is telling me that MKND truly is a diamond in the rough so Im going with that I guess.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Mar 2, 2017 14:54:42 GMT -5
Derek, darn good reply. Thank you for the reply.
Holy Mackerel that seems like a fair share of insulin you are taking. It doesn't seem to be hurting your brain cells. peace.
added: any chance Afrezza will help? (I know I am terrible)
He is from 🇨🇦 Canada
|
|
|
Post by silentknight on Mar 2, 2017 15:16:34 GMT -5
For the record. I can't believe all the doom and gloom on this board I think it's a bunch of hog wash, baloney... Everyone just do whatever you think best but just don't fall for the doom and gloom many posters are spreading. MNKD is in a new never seen before position and in my opinion great things are coming.. As far as the reverse split if it happens and I mean a big IF it happens it will be at a time when great things are in the pipe so I wouldn't count on the stock price going down to far, there are a lot of smart people out there that know a deal when they see it and will buy up all they can. We are at a time where the rubber meets the road either we go the distance or we just spin are tires and go no where. My bet is a 10-20 times banger. Call me a pumper I don't care but I know there are many here spreading fud and I think you are all getting very scared of what's to come.. Good luck. I've said my peace. R/S today and down 9%.... Any other predictions?
|
|